Repatha clinical uses
Pro Research Analysisby 
Searched over 200M research papers
Repatha Clinical Uses: Indications and Patient Populations
Repatha (evolocumab) is a PCSK9 inhibitor approved for several clinical uses related to cholesterol management and cardiovascular risk reduction. Its primary indication is for patients with hypercholesterolemia, especially those who cannot achieve target LDL-C levels with statins and other lipid-lowering therapies alone. This includes patients with both heterozygous familial hypercholesterolemia (HeFH) and the rarer homozygous familial hypercholesterolemia (HoFH), as well as those with established atherosclerotic cardiovascular disease (ASCVD) such as heart attack or stroke who require further LDL-C lowering 1234+4 MORE.
Repatha for Familial Hypercholesterolemia and High Cardiovascular Risk
Repatha is particularly valuable for patients with inherited forms of high cholesterol (HeFH and HoFH), who often struggle to control LDL-C levels with standard treatments. It is also indicated for adults with primary hyperlipidemia, including both familial and non-familial forms, and for those with mixed dyslipidemia 2356+2 MORE. In these populations, Repatha is used as an adjunct to diet and maximally tolerated statin therapy, or as monotherapy when statins are contraindicated or not tolerated 3568.
Efficacy in Lowering LDL-C and Cardiovascular Event Reduction
Clinical trials have shown that Repatha can reduce LDL-C by 50–60% when added to statin therapy, and by about 30% in patients with HoFH 3567+1 MORE. It also lowers total cholesterol, non-HDL cholesterol, apolipoprotein B, and lipoprotein(a) . In the FOURIER trial, Repatha significantly reduced the incidence of major cardiovascular events by 15% in patients with ASCVD and residual hypercholesterolemia despite statin therapy . The benefit was closely linked to the degree of LDL-C reduction, even at very low LDL-C levels .
Safety and Tolerability Profile
Repatha has demonstrated a favorable safety profile in clinical studies, with no serious adverse effects on cognitive function and good overall tolerability 1357. Common side effects include nasopharyngitis, upper respiratory tract infection, flu, back pain, and injection-site reactions such as redness or pain . Allergic reactions like rash and hives have also been reported, but serious adverse events are rare .
Administration and Dosage
Repatha is administered via subcutaneous injection, either as 140 mg every two weeks or 420 mg once a month for most adults. For adults with HoFH, the recommended dose is 420 mg once a month 358. It is available in prefilled syringes, autoinjectors, and automated mini-dosers for patient convenience .
Conclusion
Repatha is a clinically proven, effective, and well-tolerated option for patients with high cholesterol who are unable to reach LDL-C targets with standard therapies, including those with familial hypercholesterolemia and established cardiovascular disease. Its use as an adjunct to diet and statin therapy, or as monotherapy when statins are not suitable, makes it a valuable tool in reducing LDL-C and lowering the risk of major cardiovascular events 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic